基于实验室数据的集群,用于入住重症监护病房的心力衰竭患者
Sepehr Nemati1, Babak Mohammadi2, Zahra Hooshanginezhad3
1Department of Cardiology, BooAli Hospital, Azad University of Medical Sciences, Tehran, Iran.
Journal of clinical laboratory analysis
|October 5, 2024
概括
常规实验室生物标志物在ICU中确定了两个不同的心力衰竭患者表型. 这些表型显著影响死亡风险,可以通过血细胞计数和电解质水平来区分.
科学领域:
- 心脏病学 心脏病学
- 密集护理医学 密集护理医学
- 生物标志物发现发现
背景情况:
- 心力衰竭 (HF) 给医疗保健带来了巨大的负担.
- 在重症监护室 (ICU) 确定患者子组对于量身定制的治疗至关重要.
- 常规测量的实验室生物标志物可以帮助识别子组.
研究的目的:
- 在ICU入院的心力衰竭患者中确定不同的患者子组.
- 用实验室生物标志物来描述这些子组.
- 评估已确定子组的预后意义.
主要方法:
- 对接受ICU治疗的心力衰竭患者的大型数据集 (N=1176) 的分析.
- 根据实验室生物标志物对患者进行分组,以确定表型.
- 使用二进制物流模型进行特征化的集群分析.
主要成果:
- 确定了两个不同的患者群 (N=679和497).
- 集群之间死亡率的显著差异 (7.4%对21.9%).
- 集群2患者年龄较大,患慢性病率较高;显著的预测因素包括白细胞计数,MCV,红细胞分布宽度,HCT,乳酸,BUN,,和.
结论:
- 在ICU患者中使用实验室数据确定了两种心力衰竭表型.
- 这些表型对死亡率具有预后意义.
- 通过血液细胞计数,功能和血清电解质可以实现分化.
更多相关视频
相关概念视频
Heart Failure V: Nursing Interventions
2
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
2
Heart Failure IV: Classification and Diagnostic Evaluation
2
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
2
Heart Failure III: Clinical Manifestations
3
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
3
Heart Failure V: Medical Management
2
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
2
Acute Coronary Syndrome III: Diagnostic studies
3
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
3
Heart Failure VI: Adjunct Therapies
5
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
5


